Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GMAB |
---|---|---|
09:32 ET | 12177 | 22.69 |
09:33 ET | 18898 | 22.73 |
09:35 ET | 6638 | 22.66 |
09:37 ET | 7210 | 22.67 |
09:39 ET | 3085 | 22.69 |
09:42 ET | 6370 | 22.66 |
09:44 ET | 2974 | 22.71 |
09:46 ET | 2300 | 22.685 |
09:48 ET | 6707 | 22.71 |
09:50 ET | 5016 | 22.7 |
09:51 ET | 1500 | 22.665 |
09:53 ET | 3407 | 22.68 |
09:55 ET | 1046 | 22.69 |
09:57 ET | 7088 | 22.705 |
10:00 ET | 3930 | 22.705 |
10:02 ET | 5246 | 22.72 |
10:04 ET | 1608 | 22.77 |
10:06 ET | 603 | 22.785 |
10:08 ET | 9131 | 22.8 |
10:09 ET | 3050 | 22.785 |
10:11 ET | 8604 | 22.8 |
10:13 ET | 8953 | 22.81 |
10:15 ET | 9450 | 22.79 |
10:18 ET | 1151 | 22.79 |
10:20 ET | 5120 | 22.8 |
10:22 ET | 8067 | 22.82 |
10:24 ET | 8948 | 22.81 |
10:26 ET | 6186 | 22.81 |
10:27 ET | 2633 | 22.81 |
10:29 ET | 15822 | 22.83 |
10:31 ET | 16312 | 22.775 |
10:33 ET | 8388 | 22.77 |
10:36 ET | 6907 | 22.745 |
10:38 ET | 7633 | 22.745 |
10:40 ET | 400 | 22.755 |
10:42 ET | 1312 | 22.745 |
10:44 ET | 420 | 22.75 |
10:45 ET | 553 | 22.74 |
10:47 ET | 1478 | 22.73 |
10:49 ET | 2992 | 22.74 |
10:51 ET | 1258 | 22.75 |
10:54 ET | 3122 | 22.755 |
10:56 ET | 2300 | 22.745 |
10:58 ET | 18183 | 22.72 |
11:00 ET | 10600 | 22.72 |
11:02 ET | 12143 | 22.75 |
11:03 ET | 3190 | 22.8 |
11:05 ET | 2832 | 22.77 |
11:07 ET | 3118 | 22.775 |
11:09 ET | 800 | 22.775 |
11:12 ET | 1260 | 22.78 |
11:14 ET | 500 | 22.785 |
11:16 ET | 4840 | 22.78 |
11:18 ET | 3422 | 22.78 |
11:20 ET | 1649 | 22.775 |
11:21 ET | 303 | 22.775 |
11:23 ET | 600 | 22.755 |
11:25 ET | 839 | 22.745 |
11:27 ET | 2600 | 22.745 |
11:30 ET | 1210 | 22.735 |
11:32 ET | 900 | 22.72 |
11:34 ET | 500 | 22.73 |
11:36 ET | 735 | 22.725 |
11:38 ET | 1156 | 22.725 |
11:39 ET | 2596 | 22.735 |
11:41 ET | 400 | 22.72 |
11:43 ET | 200 | 22.72 |
11:45 ET | 12620 | 22.72 |
11:48 ET | 687 | 22.72 |
11:50 ET | 2817 | 22.72 |
11:52 ET | 9690 | 22.72 |
11:54 ET | 15477 | 22.695 |
11:56 ET | 4691 | 22.7 |
11:57 ET | 1100 | 22.71 |
11:59 ET | 1980 | 22.705 |
12:01 ET | 7075 | 22.73 |
12:03 ET | 10450 | 22.735 |
12:06 ET | 500 | 22.735 |
12:08 ET | 597 | 22.73 |
12:10 ET | 4637 | 22.735 |
12:12 ET | 3419 | 22.74 |
12:14 ET | 12304 | 22.77 |
12:15 ET | 2380 | 22.78 |
12:17 ET | 2155 | 22.775 |
12:19 ET | 2700 | 22.775 |
12:21 ET | 1900 | 22.785 |
12:24 ET | 4972 | 22.795 |
12:26 ET | 3427 | 22.8 |
12:28 ET | 1697 | 22.805 |
12:30 ET | 1973 | 22.8098 |
12:32 ET | 5085 | 22.805 |
12:33 ET | 14278 | 22.825 |
12:35 ET | 10815 | 22.84 |
12:37 ET | 2946 | 22.835 |
12:39 ET | 3050 | 22.84 |
12:42 ET | 2338 | 22.83 |
12:44 ET | 3319 | 22.835 |
12:46 ET | 2815 | 22.84 |
12:48 ET | 7030 | 22.86 |
12:50 ET | 8675 | 22.875 |
12:51 ET | 8677 | 22.875 |
12:53 ET | 700 | 22.88 |
12:55 ET | 917 | 22.875 |
12:57 ET | 2700 | 22.88 |
01:00 ET | 2300 | 22.88 |
01:02 ET | 1700 | 22.885 |
01:04 ET | 1706 | 22.875 |
01:06 ET | 2342 | 22.865 |
01:08 ET | 2846 | 22.845 |
01:09 ET | 1200 | 22.835 |
01:11 ET | 3231 | 22.83 |
01:13 ET | 7416 | 22.85 |
01:15 ET | 1922 | 22.84 |
01:18 ET | 3060 | 22.845 |
01:20 ET | 2683 | 22.84 |
01:22 ET | 4882 | 22.855 |
01:24 ET | 4350 | 22.85 |
01:26 ET | 2062 | 22.855 |
01:27 ET | 2457 | 22.855 |
01:29 ET | 3708 | 22.865 |
01:31 ET | 3182 | 22.85 |
01:33 ET | 2375 | 22.855 |
01:36 ET | 700 | 22.85 |
01:38 ET | 1000 | 22.845 |
01:40 ET | 3351 | 22.845 |
01:42 ET | 858 | 22.845 |
01:44 ET | 704 | 22.845 |
01:45 ET | 1900 | 22.85 |
01:47 ET | 800 | 22.845 |
01:49 ET | 4762 | 22.84 |
01:51 ET | 1092 | 22.86 |
01:54 ET | 2472 | 22.855 |
01:56 ET | 758 | 22.85 |
01:58 ET | 1997 | 22.845 |
02:00 ET | 2147 | 22.835 |
02:02 ET | 1993 | 22.835 |
02:03 ET | 1200 | 22.835 |
02:05 ET | 1819 | 22.835 |
02:07 ET | 2134 | 22.8284 |
02:09 ET | 1380 | 22.84 |
02:12 ET | 5428 | 22.815 |
02:14 ET | 900 | 22.81 |
02:16 ET | 900 | 22.82 |
02:18 ET | 961 | 22.815 |
02:20 ET | 1930 | 22.8025 |
02:21 ET | 728 | 22.8099 |
02:23 ET | 1676 | 22.81 |
02:25 ET | 100 | 22.805 |
02:27 ET | 4282 | 22.8 |
02:30 ET | 4499 | 22.8 |
02:32 ET | 3907 | 22.79 |
02:34 ET | 2400 | 22.805 |
02:36 ET | 1308 | 22.805 |
02:38 ET | 3200 | 22.805 |
02:39 ET | 1100 | 22.805 |
02:41 ET | 4251 | 22.79 |
02:43 ET | 3087 | 22.785 |
02:45 ET | 1526 | 22.785 |
02:48 ET | 10690 | 22.785 |
02:50 ET | 5882 | 22.785 |
02:52 ET | 2050 | 22.795 |
02:54 ET | 4000 | 22.815 |
02:56 ET | 4156 | 22.825 |
02:57 ET | 1578 | 22.825 |
02:59 ET | 1715 | 22.825 |
03:01 ET | 5179 | 22.825 |
03:03 ET | 2196 | 22.85 |
03:06 ET | 8208 | 22.845 |
03:08 ET | 6093 | 22.845 |
03:10 ET | 1146 | 22.845 |
03:12 ET | 5847 | 22.8399 |
03:14 ET | 1156 | 22.835 |
03:15 ET | 6209 | 22.84 |
03:17 ET | 5615 | 22.835 |
03:19 ET | 4824 | 22.8415 |
03:21 ET | 1964 | 22.8408 |
03:24 ET | 6087 | 22.835 |
03:26 ET | 7009 | 22.825 |
03:28 ET | 900 | 22.82 |
03:30 ET | 3826 | 22.815 |
03:32 ET | 3596 | 22.795 |
03:33 ET | 8904 | 22.795 |
03:35 ET | 2669 | 22.78 |
03:37 ET | 5260 | 22.775 |
03:39 ET | 6343 | 22.765 |
03:42 ET | 2920 | 22.765 |
03:44 ET | 3851 | 22.775 |
03:46 ET | 7018 | 22.77 |
03:48 ET | 7544 | 22.775 |
03:50 ET | 4108 | 22.775 |
03:51 ET | 6124 | 22.765 |
03:53 ET | 8410 | 22.755 |
03:55 ET | 6419 | 22.76 |
03:57 ET | 11533 | 22.77 |
04:00 ET | 112299 | 22.78 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Genmab A/S | 15.0B | 18.7x | +20.61% |
United Therapeutics Corp | 16.6B | 16.6x | +8.22% |
BioMarin Pharmaceutical Inc | 12.7B | 39.7x | --- |
Exact Sciences Corp | 12.9B | -74.0x | --- |
Neurocrine Biosciences Inc | 12.3B | 32.3x | +62.04% |
Qiagen NV | 9.6B | 137.2x | +12.66% |
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.0B |
---|---|
Revenue (TTM) | $2.8B |
Shares Outstanding | 661.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.98 |
EPS | $1.22 |
Book Value | $7.16 |
P/E Ratio | 18.7x |
Price/Sales (TTM) | 5.4 |
Price/Cash Flow (TTM) | 65.0x |
Operating Margin | 30.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.